Skip to main content

ProAxsis Proteinase 3 Assay CE Marked

NEW YORK (360Dx) – ProAxsis said this week it has achieved CE marking for its ProteaseTag Active Proteinase 3 immunoassay.

Proteinase 3 is a neutrophilic protease, which has been associated with the inflammation and destruction of the lung matrix in respiratory diseases including chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. ProAxsis and an unnamed US-based biotechnology company codeveloped the assay as part of an ongoing collaboration.

ProAxsis also has made its first commercial sale of the ProteaseTag Active Proteinase 3 immunoassay, it said.

The Belfast, Ireland-based company was founded five years ago and develops products to capture, detect, and measure active protease biomarkers of disease. Its portfolio includes NEATstik, a rapid test for measuring active neutrophil elastase at the point of care, which was CE marked in 2017.

ProAxsis also offers the ProteaseTag Active Neutrophil Elastase Immunoassay. Last September, it reached an agreement with Diagenics to distribute that assay in Great Britain and Ireland.